Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seongjae Kim

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Experimental Hematology & Oncology|October 23, 2025
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancerDongmi Ko, Soeun Park, Minsu Park, et al.
Cellular and Molecular Life Sciences : CMLS|May 15, 2023
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinaseJuyeon Seo, Minsu Park, Dongmi Ko, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 4, 2023
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFRSeongjae Kim, Jung Min Park, Soeun Park, et al.
International Journal of Molecular Medicine|February 6, 2026
Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancerEunsun Jung, Ji Young Kim, Dongmi Ko, et al.
Oncology Reports|November 14, 2025
C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBCEunsun Jung, Yoon-Jae Kim, Kyoungmin Lee, et al.
Theranostics|April 22, 2024
The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancerMinsu Park, Eunsun Jung, Jung Min Park, et al.
Oncogene|May 2, 2022
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock responseJi Young Kim, Tae-Min Cho, Jung Min Park, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Experimental Hematology & Oncology|October 23, 2025
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancerDongmi Ko, Soeun Park, Minsu Park, et al.
Cellular and Molecular Life Sciences : CMLS|May 15, 2023
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinaseJuyeon Seo, Minsu Park, Dongmi Ko, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 4, 2023
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFRSeongjae Kim, Jung Min Park, Soeun Park, et al.
International Journal of Molecular Medicine|February 6, 2026
Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancerEunsun Jung, Ji Young Kim, Dongmi Ko, et al.
Oncology Reports|November 14, 2025
C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBCEunsun Jung, Yoon-Jae Kim, Kyoungmin Lee, et al.
Theranostics|April 22, 2024
The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancerMinsu Park, Eunsun Jung, Jung Min Park, et al.
Oncogene|May 2, 2022
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock responseJi Young Kim, Tae-Min Cho, Jung Min Park, et al.
Pageof 4